share_log

6-K: Novo Nordisk A/S - Share Repurchase Programme

6-K: Novo Nordisk A/S - Share Repurchase Programme

6-K：諾和諾德-股票回購計劃
美股SEC公告 ·  09/09 23:15
牛牛AI助理已提取核心訊息
Novo Nordisk A/S, a leading global healthcare company, has announced the progress of its share repurchase program on September 9, 2024. The program, which began on August 7, 2024, is part of a larger 12-month share repurchase plan initiated on February 6, 2024, with a total budget of up to DKK 20 billion. As of September 6, 2024, Novo Nordisk has repurchased 12,023,313 B shares at an average price of DKK 880.98 per share, amounting to DKK 10,592,256,521. The current phase of the program aims to repurchase B shares for up to DKK 2.4 billion between August 7 and November 4, 2024. Since the last announcement, 956,187 B shares have been acquired for a total of DKK 864,550,471. Novo Nordisk now holds 13,351,944 B shares as treasury shares, which is 0.3% of the share capital. The company's shares are traded on Nasdaq Copenhagen and its ADRs on the New York Stock Exchange.
Novo Nordisk A/S, a leading global healthcare company, has announced the progress of its share repurchase program on September 9, 2024. The program, which began on August 7, 2024, is part of a larger 12-month share repurchase plan initiated on February 6, 2024, with a total budget of up to DKK 20 billion. As of September 6, 2024, Novo Nordisk has repurchased 12,023,313 B shares at an average price of DKK 880.98 per share, amounting to DKK 10,592,256,521. The current phase of the program aims to repurchase B shares for up to DKK 2.4 billion between August 7 and November 4, 2024. Since the last announcement, 956,187 B shares have been acquired for a total of DKK 864,550,471. Novo Nordisk now holds 13,351,944 B shares as treasury shares, which is 0.3% of the share capital. The company's shares are traded on Nasdaq Copenhagen and its ADRs on the New York Stock Exchange.
諾和諾德（Novo Nordisk A/S）是一家領先的全球醫療保健公司，該公司於2024年9月9日宣佈了其股份回購計劃的進展。該計劃始於2024年8月7日，是自2024年2月6日啓動的更大規模爲期12個月的股份回購計劃的一部分，總預算高達200億丹麥克朗。截至2024年9月6日，諾和諾德已經以平均每股880.98丹麥克朗的價格回購了120,233,130億股，總計10,592,256,521丹麥克朗。當前階段的計劃旨在於2024年8月7日至11月4日之間回購多達24億丹麥克朗的b股。自上次公告以來，已經收購了9,561,870億股，總額爲864,550,471丹麥克朗。諾和諾德目前擁有133,519,440億股作爲庫藏股，佔股本的0.3%。該公司股票在納斯達克哥本哈根交易，其美國存託憑證在紐約證券交易所交易。
諾和諾德（Novo Nordisk A/S）是一家領先的全球醫療保健公司，該公司於2024年9月9日宣佈了其股份回購計劃的進展。該計劃始於2024年8月7日，是自2024年2月6日啓動的更大規模爲期12個月的股份回購計劃的一部分，總預算高達200億丹麥克朗。截至2024年9月6日，諾和諾德已經以平均每股880.98丹麥克朗的價格回購了120,233,130億股，總計10,592,256,521丹麥克朗。當前階段的計劃旨在於2024年8月7日至11月4日之間回購多達24億丹麥克朗的b股。自上次公告以來，已經收購了9,561,870億股，總額爲864,550,471丹麥克朗。諾和諾德目前擁有133,519,440億股作爲庫藏股，佔股本的0.3%。該公司股票在納斯達克哥本哈根交易，其美國存託憑證在紐約證券交易所交易。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。